ARIAD Pharmaceuticals, Inc. announced that it has completed two distribution agreements for Iclusig®(ponatinib) outside of the United States. In Latin America, ARIAD and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders, have entered into an agreement for Pint Pharma to commercialize Iclusig inArgentina, Brazil, Chile, Colombia and Mexico.
ARIAD has also entered into a separate agreement with Biologix FZCo., a leading distributor of specialty pharmaceuticals in the Middle East region, for Biologix to commercialize Iclusig in the Middle East and North Africa (MENA), including in Saudi Arabia, the Gulf Coast Countries, Lebanon, and selected other countries in the region.
“Our new distribution agreements for Latin America and the Middle East and North Africa markets demonstrate our commitment to bringing Iclusig to patients around the world who are in need of this important medicine for refractory CML and Ph+ ALL, while continuing to focus our commercial resources on the U.S. market,” stated Hugh Cole, chief business officer of ARIAD. “We believe that our new partners in these geographies have the local expertise and commitment to successfully commercialize Iclusig in their markets. In addition to providing a significant share of revenues from these regions, the agreements allow future strategic optionality for ARIAD by including provisions for the buy-back of these Iclusig rights by an acquirer of ARIAD in case of a change in control of ARIAD.”
